Granahan Investment Management LLC reduced its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Rating) by 11.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,981,763 shares of the company's stock after selling 267,827 shares during the quarter. Granahan Investment Management LLC's holdings in Organogenesis were worth $15,101,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Cutler Group LP lifted its holdings in shares of Organogenesis by 114.0% in the 1st quarter. Cutler Group LP now owns 3,500 shares of the company's stock valued at $26,000 after buying an additional 28,500 shares during the period. Point72 Hong Kong Ltd acquired a new position in Organogenesis during the fourth quarter worth $31,000. Ameritas Investment Partners Inc. raised its holdings in Organogenesis by 80.1% during the first quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company's stock worth $41,000 after purchasing an additional 2,396 shares during the last quarter. Lazard Asset Management LLC raised its holdings in Organogenesis by 3,808.2% during the first quarter. Lazard Asset Management LLC now owns 9,106 shares of the company's stock worth $69,000 after purchasing an additional 8,873 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Organogenesis during the fourth quarter worth $95,000. 44.55% of the stock is owned by institutional investors and hedge funds.
Get
Organogenesis alerts:
Organogenesis Stock Performance
Organogenesis stock opened at $3.70 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.36 and a current ratio of 2.62. The stock has a fifty day moving average of $4.85 and a two-hundred day moving average of $6.00. The company has a market capitalization of $484.29 million, a price-to-earnings ratio of 6.73 and a beta of 1.86. Organogenesis Holdings Inc. has a fifty-two week low of $3.41 and a fifty-two week high of $17.39.
Analyst Upgrades and Downgrades
ORGO has been the subject of several research reports. Oppenheimer cut Organogenesis from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 10th. BTIG Research reduced their price objective on Organogenesis to $13.00 in a report on Monday, August 15th.
Insiders Place Their Bets
In other Organogenesis news, major shareholder Albert Erani sold 29,669 shares of the firm's stock in a transaction on Monday, June 13th. The stock was sold at an average price of $4.89, for a total transaction of $145,081.41. Following the completion of the transaction, the insider now owns 59,248,027 shares of the company's stock, valued at $289,722,852.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 34.40% of the stock is currently owned by company insiders.
Organogenesis Company Profile
(Get Rating)
Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.
See Also
- Get a free copy of the StockNews.com research report on Organogenesis (ORGO)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Rating).
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
